| First Author | Rehman FL | Year | 2012 |
| Journal | Cancer Discov | Volume | 2 |
| Issue | 11 | Pages | 982-4 |
| PubMed ID | 23148373 | Mgi Jnum | J:194108 |
| Mgi Id | MGI:5470352 | Doi | 10.1158/2159-8290.CD-12-0433 |
| Citation | Rehman FL, et al. (2012) The promise of combining inhibition of PI3K and PARP as cancer therapy. Cancer Discov 2(11):982-4 |
| abstractText | Analyses of in vitro and patient-derived in vivo models of breast cancer reveal that a combination of inhibitors of the enzymes PARP and phosphoinositide 3-kinase (PI3K) is a potentially effective treatment regimen for breast cancer tumors with elevated activity of the PI3K pathway. |
